Acute Leukemias in children with Down syndrome

被引：38

作者：

Zwaan, Michel C. ^{[1
]}

Reinhardt, Dirk ^{[2
]}

Hitzler, Johann ^{[3
,4
]}

Vyas, Paresh ^{[5
,6
]}

机构：

[1] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands

[2] Hannover Med Sch, Acute Myeloid Leukemia Berlin Frankfurt Munster S, D-30625 Hannover, Germany

[3] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada

[4] Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada

[5] Univ Oxford, John Radcliffe Hosp, MRC, Mol Haematol Unit, Oxford OX3 9DS, England

[6] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DS, England

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2008年 / 55卷 / 01期

关键词：

D O I：

10.1016/j.pcl.2007.11.001

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Children with Down syndrome have an increased risk for developing both acute myeloid as well as lymphoblastic leukemia. These leukemias differ in presenting characteristics and underlying biology when compared with leukemias occurring in non-Down syndrome children. Myeloid leukemia in children with Down syndrome is preceded by a preleukemic clone (transient leukemia or transient myeloproliferative disorder), which may disappear spontaneously, but may also need treatment in case of severe symptoms. Twenty percent of children. with transient leukemia subsequently develop myeloid leukemia. This transition offers a unique model to study the stepwise development of leukemia, and of gene dosage effects mediated by aneuploidy.

引用

页码：53 / +

页数：19

共 83 条

[51]

Muramatsu H, 2006, BLOOD, V108, p301B

[52] Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome [J].

Norton, Alice ;

Fisher, Chris ;

Liu, Hui ;

Wen, Qiang ;

Mundschau, Gina ;

Fuster, Jose Luis ;

Hasle, Henrik ;

Zeller, Bernward ;

Webb, David K. ;

O'Marcaigh, Aengus ;

Sorrell, April ;

Hilden, Joanne ;

Gamis, Alan ;

Crispino, John D. ;

Vyas, Paresh .

BLOOD, 2007, 110 (03) :1077-1079

[53] Excessive cardiotoxicity despite excellent leukemia-free survival for pediatric patients with down syndrome (DS) and acute myeloid leukemia (AML): Results from POG (Pediatric Oncology Group) protocol 9421. [J].

O'Brien, Maureen ;

Taub, Jeffrey ;

Stine, Kimo ;

Chang, Myron ;

Ravindranath, Yaddanapudi ;

Becton, David ;

Van Houten Dahl, Gary .

BLOOD, 2006, 108 (11) :168A-169A

[54] Incidence and clinical implications of GATA1mutations in newborns with Down syndrome [J].

Pine, Sharon R. ;

Guo, Qianxu ;

Yin, Changhong ;

Jayabose, Somasundaram ;

Druschel, Charlotte M. ;

Sandoval, Claudio .

BLOOD, 2007, 110 (06) :2128-2131

[55] GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome [J].

Pine, SR ;

Guo, QX ;

Yin, CH ;

Jayabose, S ;

Levendoglu-Tugal, O ;

Ozkaynak, MF ;

Sandoval, C .

LEUKEMIA RESEARCH, 2005, 29 (11) :1353-1356

[56] IMMUNOPHENOTYPES AND KARYOTYPES OF LEUKEMIC-CELLS IN CHILDREN WITH DOWN-SYNDROME AND ACUTE LYMPHOBLASTIC-LEUKEMIA [J].

PUI, CH ;

RAIMONDI, SC ;

BOROWITZ, MJ ;

LAND, VJ ;

BEHM, FG ;

PULLEN, DJ ;

HANCOCK, ML ;

SHUSTER, JJ ;

STEUBER, CP ;

CRIST, WM ;

CIVIN, CI ;

CARROLL, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1361-1367

[57] The proto-oncogene ERG in megakaryoblastic leukemias [J].

Rainis, L ;

Toki, T ;

Pimanda, JE ;

Rosenthal, E ;

Machol, K ;

Strehl, S ;

Göttgens, B ;

Ito, E ;

Izraeli, S .

CANCER RESEARCH, 2005, 65 (17) :7596-7602

[58] Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21 [J].

Rainis, L ;

Bercovich, D ;

Strehl, S ;

Teigler-Schlegel, A ;

Stark, B ;

Trka, J ;

Amariglio, N ;

Biondi, A ;

Muler, I ;

Rechavi, G ;

Kempski, H ;

Haas, OA ;

Izraeli, S .

BLOOD, 2003, 102 (03) :981-986

[59]

RAVINDRANATH Y, 1992, BLOOD, V80, P2210

[60] Down syndrome and acute myeloid leukemia: The paradox of increased risk for leukemia and heightened sensitivity to chemotherapy [J].

Ravindranath, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3385-3387

← 1 2 3 4 5 6 7 8 9 →